William M Pandak

US Patent:

20030092092, May 15, 2003

Filed:

Jan 29, 2002

Appl. No.:

10/060545

Inventors:

William Pandak - Richmond VA, US
Hae Min - Richmond VA, US
Shunlin Ren - Richmond VA, US

Assignee:

PAX BIOGEN CO., LTD.

International Classification:

G01N033/53
G01N033/537
G01N033/543

US Classification:

435/007930

Abstract:

The disclosure describes the presence of antitryptase autoantibody-tryptase immune complexes (the immune complexes) in sera of patients with immediate hypersensitivity diseases. Specifically, the present invention relates to a method for diagnosing of the diseases by detecting of the immune complex. More specifically the present invention includes the discovery of antitryptase autoantibody-tryptase immune complex in anaphylaxis sera and establishment of enzyme linked immunosorbent assays (ELISA) for detection of the antitryptase autoantibody-mast cell tryptase immune complex in sera of patients with anaphylaxis. The immune complexes can be used as a target for therapy of the immediate hypersensitivity diseases. The pathophysiological mechanism is provided.

US Patent:

20070275939, Nov 29, 2007

Filed:

Apr 24, 2007

Appl. No.:

11/739330

Inventors:

Shunlin Ren - Richmond VA, US
William Pandak - Richmond VA, US

International Classification:

A61K 31/56
C07J 9/00

US Classification:

514169000, 552540000

Abstract:

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear steroid metabolite that increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides (e.g. hypercholesterolemia, hyperlipidemia, and atherosclerosis) are also provided.

US Patent:

20100273761, Oct 28, 2010

Filed:

Feb 19, 2010

Appl. No.:

12/708803

Inventors:

Shunlin Ren - Richmond VA, US
William M. Pandak - Richmond VA, US

International Classification:

A61K 31/575
C07J 9/00
A61P 3/06
A61P 9/10
A61P 1/16
A61P 7/00
A61P 29/00
C12N 5/00

US Classification:

514182, 552546, 435375

Abstract:

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

US Patent:

20130143854, Jun 6, 2013

Filed:

Feb 14, 2013

Appl. No.:

13/766839

Inventors:

Virginia Commonwealth University - Richmond VA, US
William M. Pandak - Richmond VA, US

Assignee:

VIRGINIA COMMONWEALTH UNIVERSITY - Richmond VA

International Classification:

C07J 31/00

US Classification:

514182, 435375

Abstract:

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

US Patent:

20210147469, May 20, 2021

Filed:

Oct 1, 2020

Appl. No.:

17/060886

Inventors:

- Richmond VA, US
William M. Pandak - Richmond VA, US

International Classification:

C07J 31/00
C07J 9/00
A61K 31/575

Abstract:

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

US Patent:

20190169225, Jun 6, 2019

Filed:

Oct 8, 2018

Appl. No.:

16/154007

Inventors:

- Richmond VA, US
William M. Pandak - Richmond VA, US

International Classification:

C07J 31/00
C07J 9/00

Abstract:

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.

US Patent:

20180346509, Dec 6, 2018

Filed:

Feb 12, 2016

Appl. No.:

15/042244

Inventors:

- Richmond VA, US
William M. Pandak - Richmond VA, US

International Classification:

C07J 31/00

Abstract:

The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided.